QURE - uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications
- The primary and secondary endpoints for HOPE-B were met when patients with Hemophilia B were treated with etranacogene dezaparvovec.
- Marketing applications for etranacogene dezaparvovec for the treatment of patients with Hemophilia B will be submitted in both the U.S. and EU in the 1st half of 2022.
- The entire Hemophilia market is expected to grow to $18.88 billion by 2028.
- Results from 10 Huntington's disease patients in a lower dose cohort who received AMT-130 gene therapy treatment will be released in Q2 of 2022.
For further details see:
uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications